Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Serina Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.4
1.4
1.73
0.36
0.14
0.03
3.15
0.06
0.13
Cost of revenue
0.17
0.36
0.24
0.03
0.02
0.01
0.04
Gross profit
1.24
1.03
1.48
0.34
0.13
0.02
0.1
Research and development
5.78
5.83
5.9
3.71
1.46
1.03
2.39
7.48
13.2
General and administrative
3.87
5.65
8.14
6.72
6.71
5.97
3.89
9.62
11
Operating expenses
9.65
-12.3
14
10.4
8.16
7
6.28
17.1
24.2
Operating income
-6.66
-11.2
-12.6
-10.1
-7.93
-6.98
-3.13
-17
-24
Interest expense
1.1
3.34
4.9
0.53
0.21
Other non-operating income
0.03
3.51
0.32
-0.3
-0.65
-3.55
8.4
5.84
4.83
Pre-tax income
-7.73
-12.2
-11.1
8.7
10.5
5.27
-11.2
-19.2
Income tax
0.15
-0.15
0
0
0.02
Income from continuing operations
-10.4
-8.58
-10.5
Net income to minority interests
-0.06
-0.23
-0.23
-0.11
-0
-0.06
0
-0.07
-0.03
Net income
-6.58
-7.5
-12.2
-10.9
-8.68
-10.5
5.27
-11.1
-19.2
EBITDA
-6.5
-11.2
-12.2
-9.4
-3.04
-16.9
-23.9
EPS, basic
-0.21
-0.21
-0.33
-0.29
-0.23
-9.70
2.36
-1.51
-1.91
EPS, diluted
-0.21
-0.21
-0.33
-0.29
-0.23
-9.70
0.73
-1.51
-1.91
Shares, basic (weighted)
30.6
34.9
37.3
37.7
37.9
0
2.24
7.36
10.2
Shares, diluted (weighted)
30.6
34.9
37.3
37.7
37.9
0
7.35
7.36
10.2
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
7.38
6.71
2.35
0.53
0.58
0.65
7.62
3.67
3.06
Receivables
0.11
0.13
0.36
0.33
0.03
0
0.06
Other current assets
0.11
1.02
1.34
1.43
1.63
1.8
0
0.08
0.31
Total current assets
7.59
7.85
4.05
2.28
2.23
2.45
7.62
5.68
6.08
Property, plant and equipment
0.13
0.09
1.13
0.57
0.5
0.47
Lease right-of-use assets
0.73
0.67
0.46
0.38
Intangible assets
1.87
2.71
2.15
1.59
0.87
0.74
0
Total assets
9.63
10.7
7.44
3.93
3.15
3.24
8.97
6.72
6.95
Accounts payable
0.08
0.15
0.42
0.76
0.19
0.57
0.58
0.74
1.93
Accrued liabilities
0.26
0.25
0.26
0.23
0.37
0.27
0.58
1.43
1.21
Deferred revenue
0.18
0.32
0.28
0.28
Total current liabilities
2.44
3.3
5.36
8.97
10.1
1.41
2.37
3.56
Lease liabilities
0.46
0.27
0.2
Total liabilities
1.31
2.44
4.83
9.32
15
20.6
4.86
6.22
6.99
Total debt
13.2
18.1
Paid-in capital
73.8
81.5
88.4
91.8
93.9
99
0.88
45
58.5
Retained earnings
-66.6
-74.1
-86.2
-97.1
-106
-116
-33.2
-44.3
-63.5
Other comprehensive income
0.07
-0
0.07
0.14
0
-0.01
Shareholders' equity
7.28
7.45
2.22
-5.12
-11.8
-37.8
-32.3
0.64
-0.04
Minority interests
1.04
0.78
0.4
-0.28
-0.04
-0.1
0
-0.13
0
Total equity
8.32
8.23
2.62
-5.4
-11.9
-37.8
-32.3
0.51
-0.04
Total liabilities and equity
9.63
10.7
7.44
3.93
3.15
3.24
8.97
6.72
6.95
Shares outstanding
33.8
35.8
37.6
37.7
37.9
1.08
2.41
9.42
10.8
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-6.64
-7.73
-12.4
-11
-8.69
-10.5
5.27
-11.2
-19.2
Depreciation and amortization
0.17
0.06
0.39
0.7
0.09
0.1
0.1
Stock-based compensation
0.11
1.29
1.91
0.91
1
0.76
0.03
2.6
3.79
Change in payables
0.27
0.65
0.17
0.38
-0.77
0.14
0.39
-1.66
1.2
Cash from operations
-6.29
-8
-10.2
-7.82
-7.86
-5.94
-2.48
-17.1
-18
Capital expenditures
-0
-0.02
-0.64
-0.02
-0.5
-0.02
-0.06
Cash from investing
0.01
1.33
-0.36
-0.02
0.67
-0.5
-0.02
-0.06
Debt issued
0.43
Stock issued
10
5
7.8
7.2
0.5
7.3
0.02
0.01
0.02
Cash from financing
13.3
6
6.27
5.96
7.25
6
10.1
13.2
17.4
Exchange rate effect
0.12
Net change in cash
7.12
-0.67
-4.26
-1.88
0.06
0.06
7.09
-3.95
-0.62
Free cash flow
-6.29
-8.02
-10.8
-7.84
-2.98
-17.2
-18
Interest paid
0.01
0.01
0.01
0.01
0.01
0.01
0.03
0
0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.09 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-82.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
132.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
56.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-18.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-105.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
3.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
29.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
12.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
38.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2,014.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-23.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.65x
Current assets / current liabilities.
Quick ratio
6.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.12x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
27.4%
Total liabilities / total assets.
Working capital
$21.3M
Current assets - current liabilities.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.29
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
FCF yield
-39.9%
Free cash flow / market cap.
Earnings yield
-39.9%
Net income / market cap (the inverse of P/E).
What was Serina Therapeutics, Inc.'s revenue in fiscal 2025?
Serina Therapeutics, Inc. reported revenue of $130.0K for fiscal 2025, 132.1% higher than the year before.
Was Serina Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $19.2M.
How much free cash flow did Serina Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $18.0M minus capital expenditures of $59.0K left free cash flow of -$18.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.